Ryogen licenses gene patent to Invitrogen

Jan 9 2007

Ryogen LLC announced today that the company have entered into a nonexclusive license agreement with Invitrogen Corporation, whereby Invitrogen has licensed from Ryogen the patent directed to the clinically important Aminopeptidase P gene.

The US Patent No. 6,399,349 titled "Human Aminopeptidase P Gene," which is the subject of the License Agreement, covers the XPNPEP2 gene sequenced by Dr. James Ryan, Chief Scientist of Ryogen LLC. XPNPEP2 codes for the membrane- bound aminopeptidase P (AmP). This protein is a significant marker for hypertension, angioedema, rejection of kidney transplants, certain tumors and other diseases. The patent covers the cDNA and gDNA sequences encoding AmP, a method of producing recombinant AmP, diagnostics for detecting AmP abnormalities, and prevention and treatment of medical conditions, associated with the mutation of the AmP gene.

"We are happy to extend a license under the AmP Patent to Invitrogen," said Valeria Poltorak, Ryogen's Executive Vice President. "We look forward to working with Invitrogen on making this discovery available to the research community," she concluded.